1. Association of DNA Methylation at CPT1A Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study.
- Author
-
Das M, Sha J, Hidalgo B, Aslibekyan S, Do AN, Zhi D, Sun D, Zhang T, Li S, Chen W, Srinivasan SR, Tiwari HK, Absher D, Ordovas JM, Berenson GS, Arnett DK, and Irvin MR
- Subjects
- Aged, Anthropometry, Black People genetics, Blood Pressure, Carnitine O-Palmitoyltransferase physiology, Chromosomes, Human, Pair 11 genetics, Cohort Studies, Female, Humans, Male, Metabolic Syndrome ethnology, Middle Aged, Minnesota epidemiology, Oligonucleotide Array Sequence Analysis, Risk Factors, Triglycerides blood, Utah epidemiology, White People genetics, Black or African American, Carnitine O-Palmitoyltransferase genetics, CpG Islands genetics, DNA Methylation, Metabolic Syndrome genetics
- Abstract
In this study, we conducted an epigenome-wide association study of metabolic syndrome (MetS) among 846 participants of European descent in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). DNA was isolated from CD4+ T cells and methylation at ~470,000 cytosine-phosphate-guanine dinucleotide (CpG) pairs was assayed using the Illumina Infinium HumanMethylation450 BeadChip. We modeled the percentage methylation at individual CpGs as a function of MetS using linear mixed models. A Bonferroni-corrected P-value of 1.1 x 10(-7) was considered significant. Methylation at two CpG sites in CPT1A on chromosome 11 was significantly associated with MetS (P for cg00574958 = 2.6x10(-14) and P for cg17058475 = 1.2x10(-9)). Significant associations were replicated in both European and African ancestry participants of the Bogalusa Heart Study. Our findings suggest that methylation in CPT1A is a promising epigenetic marker for MetS risk which could become useful as a treatment target in the future.
- Published
- 2016
- Full Text
- View/download PDF